Astrazeneca (AZN) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Astrazeneca (AZN) over the last 16 years, with Q4 2025 value amounting to 0.43.

Astrazeneca's Equity Ratio rose 871.16% to 0.43 in Q4 2025 from the same period last year, while for Dec 2025 it was 0.43, marking a year-over-year increase of 871.16%. This contributed to the annual value of 0.43 for FY2025, which is 871.16% up from last year.
According to the latest figures from Q4 2025, Astrazeneca's Equity Ratio is 0.43, which was up 871.16% from 0.4 recorded in Q3 2025.
Astrazeneca's 5-year Equity Ratio high stood at 377.76 for Q4 2021, and its period low was 0.21 during Q2 2021.
Its 5-year average for Equity Ratio is 19.24, with a median of 0.39 in 2022.
As far as peak fluctuations go, Astrazeneca's Equity Ratio surged by 16109402.34% in 2021, and later crashed by 9989.83% in 2022.
Quarter analysis of 5 years shows Astrazeneca's Equity Ratio stood at 377.76 in 2021, then tumbled by 99.9% to 0.38 in 2022, then rose by 0.84% to 0.39 in 2023, then rose by 1.43% to 0.39 in 2024, then increased by 8.71% to 0.43 in 2025.
Its Equity Ratio was 0.43 in Q4 2025, compared to 0.4 in Q3 2025 and 0.4 in Q2 2025.

Peer Comparison